The U.S. Food and Drug Administration’s approval of Viz.ai’s hypertrophic cardiomyopathy establishes a new category for cardiovascular machine learning-based notification software.
WHY IT MATTERS
Viz.ai, a disease detection and intelligent care coordination company, said in its announcement…
Source: Healthcareitnews.com and Read More
Wellumio Expands Stroke Detection Device to U.S. Market
New Zealand-based medical device firm Wellumio has launched a subsidiary in California to accelerate US-based clinical trials and commercial rollout of its portable stroke detection
